[go: up one dir, main page]

WO2004112649A2 - Procede et appareil permettant de fournir un gaz a une zone - Google Patents

Procede et appareil permettant de fournir un gaz a une zone Download PDF

Info

Publication number
WO2004112649A2
WO2004112649A2 PCT/US2004/019599 US2004019599W WO2004112649A2 WO 2004112649 A2 WO2004112649 A2 WO 2004112649A2 US 2004019599 W US2004019599 W US 2004019599W WO 2004112649 A2 WO2004112649 A2 WO 2004112649A2
Authority
WO
WIPO (PCT)
Prior art keywords
gases
reservoir
layer
gas
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/019599
Other languages
English (en)
Other versions
WO2004112649A3 (fr
Inventor
Conti Rosati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxyband Technologies Inc
Original Assignee
Oxyband Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/781,965 external-priority patent/US7014630B2/en
Priority to CN2004800237859A priority Critical patent/CN1838976B/zh
Priority to BRPI0411651-8A priority patent/BRPI0411651A/pt
Priority to MXPA05013786A priority patent/MXPA05013786A/es
Priority to EP04755643.6A priority patent/EP1644071A4/fr
Priority to AU2004249259A priority patent/AU2004249259B2/en
Application filed by Oxyband Technologies Inc filed Critical Oxyband Technologies Inc
Priority to JP2006517434A priority patent/JP4750023B2/ja
Priority to CA2529516A priority patent/CA2529516C/fr
Publication of WO2004112649A2 publication Critical patent/WO2004112649A2/fr
Publication of WO2004112649A3 publication Critical patent/WO2004112649A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/30—Gas therapy for therapeutic treatment of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H33/00—Bathing devices for special therapeutic or hygienic purposes
    • A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H35/00—Baths for specific parts of the body

Definitions

  • the present invention relates generally to supplying a gas to an area.
  • the healing of wounds and the effect of oxygen tension has been intensively studied (1).
  • the components important in the healing process are fibroblast proliferation, angiogenesis, collagen synthesis, and reepithelialization.
  • fibroblasts are aerobic in nature. Fibroblasts are stimulated to produce collagen. While experiments from cultured fibroblasts suggest that high lactate and ascorbic acid concentration typical of hypoxic conditions may activate some of the fibroblast collagen-synthesizing enzymes, animal studies involving low, normal, and high oxygen tensions nevertheless demonstrate increased rates of collagen synthesis under hyperoxic rather than hypoxic conditions.
  • Angiogenesis appears to be stimulated by a hypoxic tissue gradient, with new capillaries extending in the direction of lower oxygen concentration. When a hypoxic gradient no longer exists, angiogenesis is minimized or static.
  • Epithelialization is also known to be related to oxygen tension, with higher rates of epithelial proliferation observed under hyperoxic as opposed to hypoxic conditions.
  • the supply of oxygen to healing wound tissue may be derived from three sources: oxygen chemically bound to hemoglobin in whole blood; oxygen dissolved in plasma; and oxygen which diffuses into plasma or tissue from the exterior. In deep wounds, the latter is of little importance. The studies of R. P.
  • Gruber et al. indicate that oxygen tension, measured polarographically, increases markedly at 3 bar of 100% O 2 in the superficial dermis (0.30-0.34 mm), while the relative oxygen concentration of the deep dermis (1.8-2.2 mm) is unchanged under the same conditions (2).
  • occlusive coverings that maintain a moist environment promote wound healing (3).
  • the changing of wound dressings may interfere with the healing process by disrupting the healing tissue where granulation and collagen synthesis has not imparted sufficient tensile strength to avoid rupture upon dressing removal.
  • a hypoxic condition may rapidly be reached. Although this condition may encourage angiogenesis, it negatively affects collagen synthesis and epithelialization.
  • various clostridium species e.g., C. perfringens and C.
  • hypoxic conditions which can also support other anaerobic flora (4).
  • hyperoxic conditions are known to reduce the concentration of other pathogens as well.
  • the increased oxygen tension in the wound most likely results directly from increased diffusion into the wound surface from the oxygen in the chamber.
  • Gruber indicates that rate of oxygen absorption from the skin is roughly proportional to oxygen concentration from nearly 0% to 30% (2). Gruber further indicates, however, that oxygen absorption tends to level off at higher oxygen concentrations. Due to the expense of large hyperbaric chambers and the systemic effects of oxygen toxicity that they may engender, topical hyperbaric chambers have been proposed. Topical chambers operating at "normal" hyperbaric pressures of 2-3 bar are difficult to seal to the body or extremity being treated, however, without interfering with blood supply to the wound locus.
  • hyperbaric chambers operating at only modestly elevated pressure have been manufactured, such as a device operating at 22 mm Hg pure oxygen (1.03 bar) (5).
  • a device operating at 22 mm Hg pure oxygen (1.03 bar) (5).
  • Such chambers are expensive and difficult to sterilize (6).
  • Cross-infection is stated to be common.
  • Ischemia compromises wound healing and wounds in aging populations are more ischemic than those in younger populations (8). It has been demonstrated in ischemic rabbit ear models that topical or hyperbaric oxygen can convert a non-healing wound into a healing wound, and that growth factors (PDGF) provide a synergistic benefit when used with oxygen
  • Topical oxygen is essential for the contraction, the dominant healing process (17). Topical oxygen has also been shown to improve the healing rate of skin ulcers and wounds where an inadequate supply of oxygen results from peripheral vascular disease or local injury to the microcirculation. Fischer showed topical hyperbaric oxygen treatment improved epithelialization and contraction of decubitus ulcers (5).
  • Utkina demonstrated that moderate increases in oxygen levels at normal atmospheric pressure increases the closure rate of open wounds (18). He showed healing rate improved with continuous exposure to 45%.
  • a number of patents have been issued that disclose the use of local generation of oxygen at the wound site to treat wounds in bandage systems using chemical reactions, oxygen saturated solutions, or electrochemical generators (see U.S. Patent Nos. 5,855,570, 5,578,022, 5,788,682, 5,792,090 and 6,000,403). These concepts have not been commercialized.
  • the present invention allows for gas to be contained simply into the wound dressing, which creates a wound environment with continuous exposure to preset oxygen levels, without need for a gas source such as a generator, saturated solution or a chemical reaction. Since the amount of oxygen consumed by metabolic processes in the wound is relatively small, the materials for the dressing and the volume of the oxygen cavity in the dressing can be selected to maintain the desired oxygen concentration for the practical life of the dressing
  • oxygen dressing can be complimentary to other therapies and can address a rate-limiting step for various types of wounds.
  • the present invention is an apparatus that is capable of providing one or more gases to a target area.
  • One embodiment of the invention is a multi-layer wound dressing comes pre-filled with high levels of oxygen between the layers.
  • the top layer is a barrier film that holds the oxygen over the wound, while the bottom layer is a high transfer rate film, attached over the wound.
  • This self-contained dressing is applied to the wound like conventional wound dressings, and can be manufactured with a similar size, weight and feel of conventional dressings or transdermal patches.
  • the dressing can also envelop the target area, such as an appendage, in a controlled environment.
  • the dressing can be in the form of a glove or mitten for hand treatments or wounds or in the form of a sock for foot or leg treatments or wounds.
  • the barrier layer holds the oxygen in the vicinity of the wound, while the permeable or porous layer allows the oxygen to diffuse into the wound fluid at a rate proportional the gradient, until the wound fluid is saturated.
  • the dressing acts like an oxygen reservoir, and as oxygen is consumed by the wound, there is a local abundant supply to be used as needed. While oxygen is a rate-limiting component in the wound healing process, the oxygen transfer across intact skin is insignificant, and oxygen consumption by a wound is a relatively small number, estimated to be 10 "4 cc/mL fluid-hr. Therefore the design of the dressing is influenced most significantly by the diffusion rates of the relevant gases through the barrier material, the target gas concentration range on the patient, the length of time the dressing may be worn, and the seal integrity of the dressing to itself and to the patient
  • the dressing would be removed by the user from a package that uses controlled atmospheric packaging (CAP) to maintain the product integrity.
  • CAP is specifically a package with high barrier properties that contains the desired ratio of gases to preserve the product.
  • CAP is well known in the food industry and examples of the types of CAP that may be used are described in U.S. Patent No. 4,895,729 and in the published literature (19, 20, 21, 22, 23).
  • the dressing will accelerate healing of acute and chronic wounds, as well as provide antibacterial and antifungal benefits.
  • Figure 1 illustrates one embodiment of a dressing system.
  • Figure 2 illustrates one embodiment of a packaging system.
  • Figure 3 illustrates one embodiment of a gas emitting pouch system.
  • Figure 4 illustrates a flow diagram for utilizing a packaging system according to one embodiment of the invention.
  • Figure 5 illustrates a flow diagram for utilizing a dressing system according to one embodiment of the invention.
  • Figure 6 illustrates one embodiment of a pouch system.
  • Figure 7 illustrates the embodiment of a glove.
  • Figure 8 illustrates the embodiment of a sock.
  • Figure 1 illustrates an apparatus for supplying one or more gases, also referred to herein as a dressing system 100.
  • the dressing system 100 is shown as an exemplary perspective cut-away view to more clearly illustrate the invention.
  • the dressing system 100 is configured to contain a gas that is dispensed to a user wearing the dressing system 100.
  • the different gases contained within the dressing system 100 may include but is not limited to oxygen, carbon dioxide, and/or nitrogen.
  • the term "gas" includes any gas or volatile.
  • the dressing system 100 includes a seal 110, an external barrier (or top layer) 120, a reservoir 130, an absorbent ring 140, an adhesive backing 150, a permeable film (or bottom layer) 160, and a compliant porous insert 170.
  • the seal 110 is configured to bond the external barrier 120 and the permeable film 160 together such that the reservoir 130 is formed.
  • the external barrier 120 is selected to be non-permeable to gases.
  • the external barrier 120 may be constructed of metallized polyester, ceramic coated polyester, polyvinylidene chloride laminates such as Saranex®, EVOH laminates such as Oxyshield®, or polyamide laminates such as Capran®.
  • the external barrier 120 may be configured to conduct heat or electrical stimulation from an external source to the user.
  • polyethylene or another infrared transmittable material may be utilized as the external barrier 120.
  • the permeable film 160 is configured to be permeable to gases.
  • the permeable film 160 may be constructed of polyurethane, silicone, polyvinylchloride, polyolefins, and the like, preferably ethylene vinyl alcohol (EVA) or EV A/polyethylene.
  • the reservoir 130 is configured to store a gas while the dressing system 100 is worn by a user. In one embodiment, the stored gas within the reservoir 130 is controUably released to the user through the permeable film 160. The amount of gas released to the user while wearing the dressing system 100 may vary according to the concentration of the gas contained within the reservoir 130 and the material used as the permeable film 160. Other factors such as temperature and atmospheric pressure may also affect the amount of gas released to the user.
  • the absorbent ring 140 may be located adjacent to the permeable film 160 and may be configured to wick away moisture from the user.
  • the adhesive backing 150 is configured to adhere the dressing system 100 to the user. Further, the adhesive backing 150 may also be utilized to prevent the gas that is delivered through the permeable film 160 to the user from escaping. In one embodiment, the adhesive backing 150 may cover the perimeter of the dressing system 100. In another embodiment, the adhesive backing may cover the entire dressing system 100 and may be integrated with the permeable film 160.
  • the adhesive backing may be comprised of adhesive used in commercially available adhesive bandages.
  • the adhesive backing maybe comprised of a gel adhesive.
  • the gel adhesive may be comprised of a hydrogel.
  • the gel adhesive may also be reusable, such that the dressing system could be removed from the user and replaced more than once.
  • the compliant porous insert 170 is configured to prevent gas debt in areas caused by pressing the external barrier 120 directly on to the permeable film 160.
  • the compliant porous insert 170 placed within the reservoir 130 and between the external barrier 120 and the permeable film 160.
  • the dressing system 100 is configured to be pre-filled with high levels of oxygen within the reservoir 130.
  • the dressing system 100 is configured to be placed over a wound of the user to help the wound heal.
  • the external barrier 120 is configured to hold the oxygen within the dressing system 100 and the permeable film 160 is a high transfer rate film and is configured to provide oxygen over the wound.
  • the external barrier 120 holds the oxygen in the vicinity of the wound, while the permeable film 160 allows the oxygen to diffuse into the wound fluid at a rate proportional the gradient, until the wound fluid is saturated.
  • the dressing system 100 acts as an oxygen reservoir; as oxygen is consumed by the wound, there is a local abundant supply of oxygen to be provided to the wound as needed.
  • the proportions of the dressing system 100 may be influenced by the diffusion rates of the relevant gases through the permeable film 160, the target gas concentration range on the user, the length of time the dressing system 100 may be worn, and the seal integrity between the dressing system 100 and the user.
  • the dressing system 100 may accelerate healing acute and chronic wounds, as well as provide antibacterial and antifimgal benefits.
  • the dressing system 100 may be configured to deliver biologically beneficial agents such as drugs, minerals, nutrition, amino acids, pH modifiers, anti-microbials, growth factors, enzymes to the user.
  • biologically beneficial agents such as drugs, minerals, nutrition, amino acids, pH modifiers, anti-microbials, growth factors, enzymes
  • integrating the delivery systems of the gas with the beneficial agent additives may lead to synergistic effects that are not achieved by just the gas or the beneficial agent additives alone.
  • these biologically beneficial agents may be delivered as microencapsulated agents incorporated in the adhesive backing 150.
  • the microencapsulated agents may be available in a gel matrix in the dressing cavity 180, accessible to the wound through pores or perforations, or using conventional transdermal technologies.
  • a substance is included within the reservoir 130 to generate gas within the reservoir 130.
  • oxygen-releasing agents may be included within the reservoir 130.
  • Oxygen releasing agents include oxygen releasing inorganic salts, hydrogen peroxide containing formulations, intercalated magnesium peroxide, sodium percarbonate, sodium carbonate and hydrogen peroxide, and the like.
  • the permeable film 160 may be deleted and the compliant porous insert 170 may be utilized to hold a substance for generating a gas within the dressing system 100.
  • the external barrier 120 is comprised of Saranex®
  • the permeable film 160 is a polyurethane high oxygen permeability film
  • these two layers are hermetically sealed around the perimeter
  • the reservoir 130 contains 98% oxygen.
  • One method of achieving the specified oxygen concentration in the reservoir 130 and to create the controlled atmospheric packaging is to (1) assemble dressing, sealing the reservoir with normal atmospheric conditions (about 21% oxygen); (2) place the dressing in the metallized film package; (3) flush the package with 100% oxygen; and (4) seal the package.
  • the gas in the reservoir 130 will come to equilibrium with the gas in the package via the permeable film 160.
  • the product is received by the customer and opened, the gas in the reservoir will achieve 98% oxygen.
  • the materials and dimensions used are determined by taking into account these objectives.
  • the dressing system as described herein may further comprise a septum, which is defined herein as a septum, a valve, a Luer-type fitting or any resealable opening through which one or more gases can be introduced into the dressing system, then resealed to prevent the one or more gases from escaping.
  • the dressing system of this embodiment may be applied to the wound, and then the one or more gases in the desired ratio may be introduced into the dressing system, e.g., with a syringe.
  • the septum would also allow for refilling of the dressing system, if desired.
  • Figure 2 illustrates a packaging system 100.
  • the packaging system 100 is shown as an exemplary perspective cut-away view to more clearly illustrate the invention.
  • the packaging system 200 is configured to contain a gas within an enclosed container 210, which is within the packaging system.
  • the different gases contained within the dressing system 100 may include but is not limited to oxygen, carbon dioxide, and/or nitrogen.
  • the enclosed container 210 is also configured to hold the dressing system 100 as shown and described corresponding to Figure 1. Once the enclosed container 210 is sealed, the enclosed container is substantially impermeable; the gas within the enclosed container 210 substantially remains within the enclosed container 210.
  • the enclosed container 210 utilizes controlled atmospheric packaging (CAP) to maintain the environment within the enclosed container 210.
  • CAP is a package with high barrier properties that contains the desired ratio of gases to preserve the internal environment.
  • the gas within the enclosed container 210 may permeate the dressing system 100 through the permeable film 160.
  • the packaging system 200 may be utilized to store the dressing system 100 without degrading the gas stpred within the reservoir 130 within the dressing system 100 when the gas within the reservoir 130 and the gas within the enclosed container 210 are the same.
  • the packaging system 200 may be utilized to change the concentrations of gases in the dressing system 100.
  • the gas constituents stored within the enclosed container 210 diffuse into the dressing system 100 when the concentration of the gas within the container 210 is higher in concentration compared to the gas within the dressing system 100.
  • the gas constituents stored within the dressing system 100 diffuse into the container 210 when the concentration of the gas within the container 210 is lower in concentration compared to the gas within the dressing system 100.
  • the gases may diffuse through the permeable film 160 until the constituents reach equilibrium, the same concentrations on both sides of the permeable film.
  • Figure 3 illustrates a gas emitting pouch system 300.
  • the gas emitting pouch system 300 is shown as an exemplary perspective cut-away view to more clearly illustrate the invention.
  • the gas emitting pouch system 300 is configured to contain a gas that is dispensed to the local area surrounding the gas emitting pouch system 300.
  • the different gases contained within the gas emitting pouch system 300 may include but is not limited to oxygen, carbon dioxide, and/or nitrogen.
  • the gas emitting pouch system 300 includes a first permeable film 310, a second permeable film 320, and a reservoir 330.
  • the first permeable film 310 is coupled with the second permeable film 320 and forms the reservoir 330 for storing gas within the gas emitting pouch system 300.
  • the first and second permeable films 310 and 330 may be constructed of polyurethane, polyethylene, silicone films, polyvinylchloride, and the like.
  • the reservoir 330 is configured to store a gas while the gas emitting pouch system
  • the stored gas within the reservoir 330 is controUably released to the area surrounding the gas emitting pouch system 300 through the first and second permeable films 310 and 320.
  • the amount and rate of gas released through the gas emitting pouch system 300 may vary according to the concentration gradients of the gas across the permeable films that comprise the walls of reservoir 330 and the materials used as the first and second permeable films 310 and 320.
  • 310 and 320 can be the same or different materials.
  • the amount and rate of release of gas can be different on the opposite sides, this can occur when 310 and 320 have different permeabilities. Other factors such as temperature, humidity, and atmospheric pressure may also affect the amount of gas released.
  • the gas emitting pouch system 300 is configured prefilled with the desired gas concentrations and is stored within the packaging system 200 ( Figure 2) prior to releasing gas into the surrounding environment, also prefilled with the same gas concentrations as in the gas emitting pouch, in order to maintain the levels in the pouch.
  • the gas within the reservoir 330 within the gas emitting pouch system 300 comes to equilibrium within the packaging system 200 so that both the pouch and the package reach the target concentrations
  • the gas emitting pouch system 300 is configured to be placed in an environment where the gas stored within the reservoir 330 is released steadily into the surrounding environment, as the gradient doesn't change appreciably.
  • the release rate of gas from the reservoir 330 into the surrounding environment slows as the surrounding environment becomes saturated with the gas. Subsequent to the saturation, the gas emitting pouch system 300 acts as a gas reservoir; as gas is dissipated from the surrounding environment, there is a local supply of gas within the reservoir 330 to be provided to the surrounding environment, governed by the transfer rate across the permeable film.
  • the gas emitting pouch 300 has many applications which may include non- medical applications such as applying the gas emitting pouch 300 to effect environments in containers for any purpose such as lab experiments, food preservation, to accelerate degradation, to prevent corrosion, and the like.
  • a gas-retaining object is placed within the packaging system 200.
  • the gas-retaining object is the dressing system 100.
  • the gas-retaining object is gas emitting pouch system 300.
  • the gas-retaining object may be any item that is configured to retain and controUably release a gas from the object.
  • the packaging system 200 is flushed with a gas.
  • the packaging system 200 is flushed with the same gas contained with the gas-retaining object.
  • the dressing system 100 may be pre-filled with oxygen and placed within the packaging system. By flushing the packaging system 200 with oxygen, the packaging system 200 ensures that the dressing system 100 retains the pre-filled oxygen content.
  • the packaging system 200 is flushed with a different gas than the gas contained with the gas-retaining object.
  • the dressing system 100 may contain air that contains other gases in addition to oxygen and may be placed within the packaging system 200.
  • the packaging system 200 diffuses the dressing system 100 with additional oxygen until the gas within the packaging system 200 and the gas within the dressing system 100 have reached an equilibrium.
  • the packaging system 200 is sealed after placing the gas-retaining object within the packaging system 200 and flushing the packaging system 200 with a gas.
  • an exchange of gas occurs until an equilibrium is achieved.
  • the gas may be exchanged through the permeable film 160 ( Figure 1).
  • the packaging system 200 may be opened to remove the gas-retaining object.
  • the packaging system 200 may be utilized to store the gas-retaining object without degrading the gas within the gas-retaining object.
  • the packaging system 200 may be utilized to infuse the gas-retaining object with a gas.
  • the flow diagram in Figure 5 illustrates an exemplary process of utilizing the dressing system 100 according to one embodiment.
  • the dressing system 100 is removed from a packaging.
  • the dressing system 100 is adhered to a user.
  • the dressing system 100 may cover a wound or broken skin of the user.
  • the dressing system 100 utilizes the adhesive backing 150 to adhere the dressing system 100 to the user.
  • a seal is formed between the dressing system 100 and the user.
  • the adhesive backing 150 forms the seal between the dressing system 100 and the user.
  • gas is supplied from the dressing system 100 to the user.
  • the permeable film 160 is positioned over the wound or broken skin of the user and allows the gas from the dressing system 100 to be supplied to wound of the user.
  • the permeable film 160 may be positioned over intact skin of the user and allows the gas from the dressing system 100 to be supplied to the skin of the user.
  • the gas from the dressing system 100 may be supplied to the skin of the user.
  • the gas within the reservoir 130 of the dressing system 100 may be stored until additional gas is supplied to the user through the permeable film 160.
  • the packaging system comprises any of the packaging systems described herein and further comprises a septum, which as defined herein may be a septum, a valve, Luer lock or any resealable opening, through which one or more gases can be introduced into the packaging system, then resealed to prevent gases from escaping.
  • the packaging system may be charged with the one or more gases in the desired ratio on site (e.g., hospital, doctor's office).
  • the adhesive layer may comprise a gel.
  • the gel may have semi-adhesive properties, such that the same dressing system can be removed and replaced repeatedly. Examples of gels that may be used are described in U.S. Patent Nos. 4,839,345, 5,354,790 and 5,583,114.
  • FIG. 6 illustrates a pouch system 600.
  • the pouch system 600 is configured to emit gas into a local environment, similar to the gas emitting pouch system 300.
  • the pouch system 600 includes a first layer 610 and a second layer 630.
  • the first layer 610 and the second layer 630 may be permeable to gases.
  • the first layer 610 and the second layer 630 are bonded through an intermediate layer 620.
  • the intermediate layer 620 provides the pouch system 600 a more resilient and durable seal between the first layer 610 and the second layer 630 by diverting the load so that more robust shear force is applied to a higher bond strength seal rather than strictly a design that puts all the internal pressure and load on a peel strength surface.
  • the seal between the first layer 610 and the second layer 630 is reinforced.
  • Another embodiment of the invention is an apparatus that envelops a target area, such as an appendage, in a controlled environment.
  • the opening is secured around the appendage.
  • the apparatus can be in the form of a glove or mitten for hand treatments or wounds or in the form of a sock for foot or leg treatments or wounds.
  • a glove or mitten would be secured around a patient's hand or arm and a sock would secured around a patient's ankle or leg.
  • the apparatus can be prefilled in the reservoir, as described herein and packaged in a CAP environment.
  • the apparatus can also be packaged in a CAP environment that facilitates the exchange of gases such that the reservoir achieves the target ratios of gases passively through diffusion in storage, as described herein.
  • the apparatus can also be filled or recharged according to any of the methods described herein.
  • Figure 7 illustrates a glove for use in hand/arm treatments or wounds. A side view
  • the inner layer 710 is a permeable film, as described herein, which is permeable to oxygen and/or other gases.
  • the outer layer 720 is an external barrier, as described herein, selected to be less permeable to oxygen and/or other gases.
  • the two layers form a reservoir 730 between them that may contain one or more gases, gel, fluid, cushioning material, resilient porous material, or a combination thereof, or as described herein.
  • Figure 8 illustrates a sock for use in foot/leg treatments or wounds.
  • a top view 800 A, a side view 800C and a front view 800D are shown.
  • a cross-section 800B of section A-A of the sock is also shown.
  • the inner layer 810 is a permeable film, as described herein, which is permeable to oxygen and/or other gases.
  • the outer layer 820 is an external barrier, as described herein, selected to be less permeable to oxygen and/or other gases.
  • the two layers form a reservoir 830 between them that may contain one or more gases, gel, fluid, cushioning material, resilient porous material, or a combination thereof or as described herein.
  • a further embodiment of the invention is an apparatus wherein the inner and/or outer layers further comprise ribs.
  • the ribs allow the one or more gases in the reservoir to be applied to the target area even when pressure is exerted on the apparatus from an external source.
  • Other embodiments of the invention can also be an apparatus in the form of a blanket, an oxygen mask, a wrap, or an eye patch. These other embodiments may be use to supply oxygen or other gases to target areas such as the face or eye by placing the permeable layer on the target area and securing the apparatus to a patient either externally by mechanical means, i.e., gravity, by wrapping a securing tape or material around it, or by sealing the apparatus directly to the target area with an adhesive seal around the perimeter or other surfaces.
  • the present invention is useful for wound healing for human and animal patients, for use in laboratories, and anywhere a specific gas or combination of gases is required to reach a specific, discrete site.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

L'invention concerne un appareil permettant de fournir un ou plusieurs gaz, tels que l'oxygène, à une zone cible, qui comprend une couche supérieure et une couche inférieure scellées autour de leurs périmètres afin de former un réservoir entre lesdites couches. La couche supérieure est imperméable aux gaz et la couche inférieure est très perméable aux gaz, le réservoir contenant un ou plusieurs gaz. L'invention concerne également un procédé utilisant ledit appareil pour fournir de l'oxygène à une blessure afin d'améliorer sa cicatrisation.
PCT/US2004/019599 2003-06-18 2004-06-18 Procede et appareil permettant de fournir un gaz a une zone Ceased WO2004112649A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2529516A CA2529516C (fr) 2003-06-18 2004-06-18 Procede et appareil permettant de fournir un gaz a une zone
BRPI0411651-8A BRPI0411651A (pt) 2003-06-18 2004-06-18 método e aparelho para suprimento de gás para uma área
MXPA05013786A MXPA05013786A (es) 2003-06-18 2004-06-18 Metodo y aparato para suministrar gas a un area.
EP04755643.6A EP1644071A4 (fr) 2003-06-18 2004-06-18 Procede et appareil permettant de fournir un gaz a une zone
AU2004249259A AU2004249259B2 (en) 2003-06-18 2004-06-18 Method and apparatus for supplying gas to an area
CN2004800237859A CN1838976B (zh) 2003-06-18 2004-06-18 向一部位供给气体的方法和设备
JP2006517434A JP4750023B2 (ja) 2003-06-18 2004-06-18 気体を領域に供給する方法及び装置

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47974503P 2003-06-18 2003-06-18
US60/479,745 2003-06-18
US10/781,965 2004-02-18
US10/781,965 US7014630B2 (en) 2003-06-18 2004-02-18 Tissue dressing having gas reservoir
US55163804P 2004-03-08 2004-03-08
US60/551,638 2004-03-08

Publications (2)

Publication Number Publication Date
WO2004112649A2 true WO2004112649A2 (fr) 2004-12-29
WO2004112649A3 WO2004112649A3 (fr) 2005-05-12

Family

ID=33545339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/019599 Ceased WO2004112649A2 (fr) 2003-06-18 2004-06-18 Procede et appareil permettant de fournir un gaz a une zone

Country Status (8)

Country Link
EP (1) EP1644071A4 (fr)
JP (1) JP4750023B2 (fr)
CN (1) CN1838976B (fr)
AU (1) AU2004249259B2 (fr)
BR (1) BRPI0411651A (fr)
CA (1) CA2529516C (fr)
MX (1) MXPA05013786A (fr)
WO (1) WO2004112649A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008529739A (ja) * 2005-02-17 2008-08-07 オキシバンド テクノロジーズ インコーポレイテッド ガスをエリアに供給する方法および装置
JP2010508088A (ja) * 2006-10-25 2010-03-18 リバルシオ コーポレイション 傷のケアおよび処置の方法
JP2014111648A (ja) * 2006-10-25 2014-06-19 Revalesio Corp 傷のケアおよび処置の方法
CN106861051A (zh) * 2017-03-30 2017-06-20 长春长理光学精密机械有限公司 一种能封闭光辐射和气体的治疗装置
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US7832920B2 (en) 2006-10-25 2010-11-16 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
MX2010011856A (es) 2008-05-01 2011-02-15 Revalesio Corp Composiciones y métodos para tratar trastornos digestivos.
SE0801490A0 (sv) 2008-06-24 2009-12-25 Moelnlycke Health Care Ab Sårförband
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
CN102985073B (zh) 2010-05-07 2015-03-25 利发利希奥公司 用于增强生理性能和恢复时间的组合物和方法
MX2013001636A (es) 2010-08-12 2013-05-01 Revalesio Corp Composiciones y metodos para el tratamiento de taupatias
CN105664351A (zh) * 2014-07-13 2016-06-15 王丽 用于疤痕修复节约成本的医疗指套
CN105536130A (zh) * 2014-07-13 2016-05-04 王丽 一种降低疤痕修复成本的医疗指套
CN105664349A (zh) * 2014-07-13 2016-06-15 王丽 美容用新型指套
CN105664350A (zh) * 2014-07-13 2016-06-15 王丽 一种用于美容的指套
CN105749410A (zh) * 2014-07-13 2016-07-13 王丽 疤痕修复用新型指套
CN105749411A (zh) * 2014-07-13 2016-07-13 王丽 一种疤痕修复用新型医疗指套
CN105749409A (zh) * 2014-07-13 2016-07-13 王丽 用于疤痕修复的指套
MX369526B (es) * 2015-06-30 2019-11-08 Kimberly Clark Co Parche de espuma e hidrogel para suministrar oxigeno y metodo de fabricacion.
CN107874913A (zh) * 2017-12-19 2018-04-06 大连海事大学 一种基于液体材料供氧的伤口敷料及其生产方法
CN107961114A (zh) * 2017-12-19 2018-04-27 大连海事大学 一种基于固体颗粒供氧的伤口敷料及其生产方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747841A (en) * 1985-03-19 1988-05-31 Yasuro Kuratomi Methods and instruments of moxibustion
JPS645548A (en) * 1987-06-29 1989-01-10 Paramount Bed Kk Bedsore treatment aid device
AU678764B2 (en) * 1992-06-03 1997-06-12 Case Western Reserve University Bandage for continuous application of biologicals
US5788682A (en) * 1995-04-28 1998-08-04 Maget; Henri J.R. Apparatus and method for controlling oxygen concentration in the vicinity of a wound
US5792090A (en) * 1995-06-15 1998-08-11 Ladin; Daniel Oxygen generating wound dressing
EP0999041A3 (fr) * 1998-11-03 2001-01-31 Mitsubishi Polyester Film GmbH Feuille multicouche comprenant une feuille de polyester orientée biaxialement présentant des bonnes propriétés de barrière à l'oxygène, procédé de fabrication et utilisation
WO2000074616A1 (fr) * 1999-06-02 2000-12-14 Tano Robert S Pansement de premiers soins a usages multiples
WO2001005445A2 (fr) * 1999-07-19 2001-01-25 Coloplast A/S Dispositif generant du dioxyde de carbone
US6471685B1 (en) * 2000-05-18 2002-10-29 David James Johnson Medical dressing assembly and associated method of using the same
US6767342B1 (en) * 2001-04-23 2004-07-27 Evelyna D. Cantwell Oxygen bandage system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1644071A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008529739A (ja) * 2005-02-17 2008-08-07 オキシバンド テクノロジーズ インコーポレイテッド ガスをエリアに供給する方法および装置
JP2010508088A (ja) * 2006-10-25 2010-03-18 リバルシオ コーポレイション 傷のケアおよび処置の方法
JP2014111648A (ja) * 2006-10-25 2014-06-19 Revalesio Corp 傷のケアおよび処置の方法
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
CN106861051A (zh) * 2017-03-30 2017-06-20 长春长理光学精密机械有限公司 一种能封闭光辐射和气体的治疗装置

Also Published As

Publication number Publication date
JP2007524447A (ja) 2007-08-30
WO2004112649A3 (fr) 2005-05-12
MXPA05013786A (es) 2006-02-28
EP1644071A2 (fr) 2006-04-12
CN1838976A (zh) 2006-09-27
JP4750023B2 (ja) 2011-08-17
CA2529516A1 (fr) 2004-12-29
EP1644071A4 (fr) 2013-11-27
AU2004249259A2 (en) 2004-12-29
AU2004249259B2 (en) 2011-04-07
AU2004249259A1 (en) 2004-12-29
BRPI0411651A (pt) 2006-08-08
CN1838976B (zh) 2011-11-09
CA2529516C (fr) 2012-06-12

Similar Documents

Publication Publication Date Title
US7263814B2 (en) Method and apparatus for supplying gas to an area
CA2529516C (fr) Procede et appareil permettant de fournir un gaz a une zone
US7762045B2 (en) Method and apparatus for supplying gas to an area
US5792090A (en) Oxygen generating wound dressing
US8900209B2 (en) Method and apparatus for supplying gas to an area
AU716088B2 (en) Oxygen producing bandage
US9017717B2 (en) Bandage for facilitating transdermal respiration and healing
AU2009283998A1 (en) Hyperbaric dressing and method
US9572757B2 (en) Method for oxygen treatment of intact skin
MX2007010053A (es) Metodo y aparato para suministrar gas a un a
US20250268932A1 (en) Oxygen-containing preparation for treating acne and wounds, a preparation method and an application device thereof
WO2001005445A2 (fr) Dispositif generant du dioxyde de carbone
CN116059097A (zh) 一种供氧装置治疗伤口愈合的方法和耗材
CN101626805A (zh) 利用超声波的氧疗

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480023785.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2529516

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/013786

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006517434

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004755643

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004249259

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2004249259

Country of ref document: AU

Date of ref document: 20040618

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004755643

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase in:

Ref document number: PI0411651

Country of ref document: BR